Key negative regulatory pathways or ‘checkpoints’, such as the PD-1/PD-L1 pathway, physiologically control auto-reactivity, and the improved understanding of their involvement in cancer is revolutionizing tumor immunotherapy. This evidence concerns the gene PDCD1 and cancer.